Does progesterone improve outcome in diffuse axonal injury?

Area of Science:

• Neuroscience
• Clinical Medicine
• Pharmacology

Background:

• Progesterone demonstrates therapeutic potential in animal models of traumatic brain injury (TBI).
• Clinical evidence for progesterone's efficacy in TBI remains inconsistent.
• Diffuse axonal injury (DAI) represents a heterogeneous form of TBI requiring specific investigation.

Purpose of the Study:

• To evaluate the neuroprotective effects of progesterone in patients diagnosed with DAI.
• To assess the impact of progesterone on functional recovery and mortality in DAI patients.

Main Methods:

• A randomized clinical trial involving 48 DAI patients (Glasgow Coma Scale 3-12) admitted within 4 hours post-injury.
• Patients received either progesterone (1 mg/kg every 12 hours for 5 days) or a placebo (control group).
• Outcomes were measured using the extended Glasgow Outcome Scale (GOS-E), Functional Independence Measure (FIM) scores, and mortality rates at 6-month follow-up.

Main Results:

• The progesterone group showed significantly higher GOS-E and FIM scores compared to the control group at 6 months (p < 0.01 and p < 0.05, respectively).
• Mortality was observed in the control group, but not in the progesterone group (p < 0.05).
• No adverse events were associated with progesterone administration during the study period.

Conclusions:

• Progesterone may possess neuroprotective properties beneficial for patients with DAI.
• Larger clinical trials are warranted to validate progesterone as a potential therapeutic agent for DAI.